The Need for Patients
is
The Need to Convince
Patients are Fundamental for an Organization’s Survival

Why Cryonics is a Legitimate Service to Market and Sell in Asia

Cryonics proposes to use an experimental treatment on human patients with no expectation that clinical trials will be completed anytime in the near future. This has created some controversy.

Despite this, Cryopreservation is the medically conservative course of action (in the best sense of the word "conservative.").

Once convinced, terminally ill patients will especially gravitate towards the Cryonics Choice in greater and greater numbers.

Conventional medical criteria pronounce the Cryopreserved patient "dead." These criteria are disputed by those who support Cryonics, who argue that future medical capabilities should be able to decisively contradict this diagnosis by restoring patients Cryopreserved under favorable conditions (and many Cyopreserved under less than favorable conditions) to full physical and mental health.

If there is a debate about whether or not a patient is dead, it would seem inappropriate to resolve the dispute by burying or burning them, particularly if this course of action is against the wishes of the patient. Unfortunately, current legal and social environments produce this outcome all too often.

At some future date, we will have direct experimental proof that today's Cryopreserved patients either can or cannot be revived by future medical technology. Unfortunately, most of us must decide today if we wish to pursue this option.

It is worth pointing out that a fairly wide range of simple tissue types have been successfully Cryopreserved and then re-warmed, including very early human embryos, sperm, skin, bone, red and white blood cells, bone marrow and others.

How might we evaluate Cryonics?

Broadly speaking, there are two available courses of action:

(1) Sign up or (2) Do nothing.

Cryonics Payoff Matrix

  It works It doesn't work
Sign up Live Die, lose life insurance
Do nothing Die Die

And there are two possible outcomes:

(1) It works or (2) It doesn't.

This leads to the payoff matrix.

In using such a payoff matrix to evaluate the possible outcomes, we must decide what value the different outcomes have.

What value do we place on a long and healthy life?

What does Cryonics cost and what (presumably negative) value do we place on being dead?

In the absence of direct experimental results in one direction or the other, what estimate do we make of the chances that it will work?

These are all question that the individual must answer for him or herself in making a decision as to whether to commit valuable resources to this end-of-life choice. It is due diligence, pure and simple.

Bottom line, Cryopreservation is not unlike a choice to have an expensive funeral and, as in China today, you will be expected to fund an expensive burial plot; sometimes in the neighborhood of $32,000 to $160,000 and higher:

“These days the cost of living is unaffordable, and the cost of death is even more expensive. Maybe we’ll have to have our ashes thrown out after death,” a Beijing resident surnamed Sun said in an interview. “If you want to buy a grave plot, you have to pay 200,000 yuan (U.S. $31,766),” she complained. Another Beijing resident, surnamed Dong, said grave prices are now even higher than housing prices. “Usually a burial plot of about 50 square meters (540 square feet) will cost a half or a full million Yuan” (U.S. $80,000 to $160,000). Insurance is sold, funerals are sold and burial plots are sold. It makes no sense to think that Cryonics and Cryopreservation cannot be sold. Or, that there would be any regulatory impediments in Asia restricting a sales organization engaging in this activity for a profit.

At some point in time Cryopreservation my track the same market path as the breast implant market once traveled. The first implant clinics were thought of as performing unnecessary and dangerous procedures only to find, in a few years, the industry had “women lining-up around the block” metaphorically speaking. For the terminally ill patients, this might just be the future of “the extent of the market” for cryonics.

We believe that this is a legitimate service to sell and it will be highly profitable in Asia